Precision Biosciences

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Precision BioSciences (DTIL) are up as the company inks a gene-editing deal with Novartis to develop a potentially curative treatment for disorders like sickle cell disease.

Precision BioSciences' (DTIL) Stock Up This Week: Here's Why

Sorrento Therapeutics Inc

Tencent Music Entertainment Group 

Which penny stocks are you watching right now? The post Looking For the Best Penny Stocks to Buy?

Looking For the Best Penny Stocks to Buy? 3 to Watch

Novartis

DTIL stock is advancing in early trading today after Precision BioScience announced a partnership with Novartis, a leading drug maker. The post Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal appeared first on InvestorPlace.

Precision BioSciences (DTIL) Stock Treks Higher on Novartis Deal

Precision BioSciences Inc (NASDAQ: DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE: NVS)  Precision will develop a custom ARCUS nuclease that will be designed to.

Why Precision BioSciences Shares Are Surging Today

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it has agreed to sell 35,971,224 shares of its common stock at a price of $1.39 per share, by way of an underwritten offering, for gross proceeds of approximately $50.0 million. The offering is expected to close on or about June 24, 2022, subject to customary closing conditions. A

Precision BioSciences Announces $50 Million Offering of Common Stock

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced it has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis Pharma AG (the “Agreement”). As part of the Agreement, Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a t

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ: DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a.

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced its latest program updates across its allogeneic CAR T pipeline. The Company provided new clinical data and outlined the opportunity for its lead candidate, PBCAR0191, as a potential first-in-class allogeneic CD19 CAR T for the growing autologous CAR T relapsed patient population with

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will share an update on its allogeneic CAR T programs during a company-hosted webcast and conference call on June 8, 2022 at 8:00 AM ET. "We look forward to sharing the recent developments on our CAR T programs, including the latest clinical data on our potential first

Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the Jefferies Healthcare Conference taking place June 8-10, 2022. Details for the in-person fireside chat are as follows: Date: Thursday, June 9, 2022 Time: 4:00 PM ET Location: New York Marriott Marquis The fireside chat will be available via a liv

Precision BioSciences to Participate in Upcoming Jefferies Healthcare Conference

DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Melinda Brown has been appointed as a Director on the Company's Board of Directors and Chair of the Board's Audit Committee. Ms. Brown is a financial expert with proven experience leading accounting, finance and enterprise risk management teams in large, public companies. “Melind

Precision BioSciences Appoints Melinda Brown to Board of Directors

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that Juli Blanche has been appointed Chief People Officer and a member of the senior leadership team at Precision BioSciences. Ms. Blanche is a human resources (HR) executive with over 25 years of strategic business partnership and enterprise leadership experience in the pharmaceutica

Precision BioSciences Appoints Juli Blanche as Chief People Officer

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical research from its ongoing in vivo gene editing program targeting hepatitis B virus (HBV) has been published online in Molecular Therapy. Data from this study, “Targeting the Hepatitis B cccDNA with a Sequence-Specific ARCUS Nuclease to Eliminate Hepatitis B Virus In Vivo,”

Precision BioSciences Announces Publication in Molecular Therapy of ARCUS® In Vivo Gene Editing as a Promising Therapeutic Approach to Cure Chronic Hepatitis B Infection

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ASGCT22--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced preclinical data will be presented this week on ARCUS genome editing including two oral presentations and two posters at the American Society of Gene & Cell Therapy (ASGCT), May 16-19, 2022 at the Walter E. Washington Convention Center in Washington, D.C. “The preclinical findings

Precision BioSciences Announces Preclinical Data Showcasing Premier In Vivo Gene Editing Capabilities at American Society of Gene & Cell Therapy Annual Meeting

DTIL has been lagging due to poor durability data. The company stock has been lagging due to market indifference.

Precision Bio: Another CAR-T Laggard With No Solid Prospects

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.69% and 33.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q1 Loss, Misses Revenue Estimates

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the first quarter ended March 31, 2022 and provided a business update. “We continue to focus on execution and build on the utility of ARCUS as a premier genome editing platform to develop novel treatments for cancer and genetic diseases. We believe the differenti

Precision BioSciences Reports First Quarter 2022 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that four abstracts, including one from a research and license collaboration, were accepted by the American Society of Gene & Cell Therapy (ASGCT) and will be presented as posters and oral presentations at the upcoming annual meeting on May 16-19, 2022 at the Walter E. Washington

Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the first quarter 2022 and provide a business update on May 9, 2022. Precision BioSciences also announced that Michael Amoroso, Chief Executive Officer will participate in the H.C. Wainwright Global Investment Conference on May 24, 2022. Deta

Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022

Precision BioSciences (DTIL) delivered earnings and revenue surprises of 20.83% and 23.10%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q4 Loss, Misses Revenue Estimates

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced financial results for the fourth quarter and fiscal year ended December 31, 2021. “Precision BioSciences made significant progress in 2021 toward validating our differentiated ARCUS gene editing platform to improve human health. Our team advanced two ex vivo CAR T product candidates t

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)---- $DTIL #ARCUS--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that it will publish financial results for the fourth quarter and fiscal year 2021 and provide a business update on March 15, 2022. About Precision BioSciences, Inc. Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2021 Results on March 15, 2022

On Precision BioSciences' (DTIL) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline.

What to Expect From Precision BioSciences (DTIL) Q4 Earnings

Precision BioSciences (DTIL) closed the most recent trading day at $4.82, moving -0.62% from the previous trading session.

Precision BioSciences (DTIL) Stock Sinks As Market Gains: What You Should Know

In the latest trading session, Precision BioSciences (DTIL) closed at $4.86, marking a +0.83% move from the previous day.

News for Precision Biosciences Stock (DTIL)